May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin) in Patients With Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • P. Tsai
    Ophthalmology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
  • K. K. Kamat
    Ophthalmology, RFUMS/ The Chicago Medical School, Chicago, Illinois
  • N. J. Pathak
    Ophthalmology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
  • K. Z. Danek
    Ophthalmology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
  • R. M. Ahuja
    Ophthalmology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
  • Footnotes
    Commercial Relationships P. Tsai, None; K.K. Kamat, None; N.J. Pathak, None; K.Z. Danek, None; R.M. Ahuja, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1419. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Tsai, K. K. Kamat, N. J. Pathak, K. Z. Danek, R. M. Ahuja; Intravitreal Bevacizumab (Avastin) in Patients With Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1419. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine the efficacy of intravitreal bevacizumab in patients with proliferative diabetic retinopathy with vitreous hemorrhage and/or iris neovascularization (NVI) not amenable to panretinal photocoagulation.

Methods:: A retrospective analysis of 14 eyes of 12 patients given intravitreal injections of bevacizumab for proliferative diabetic retinopathy was performed at the Stroger Hospital of Cook County, Division of Ophthalmology. All patients enrolled received informed consent and a complete ophthalmic examination. Patients received 1.25 mg of bevacizumab in a 0.05 ml intravitreal dose. Post-injection examinations were performed between 1 to 3 days and then at 1 to 2 months.

Results:: Of the 12 patients half were female, and the average age was 52 years (28-69 years). Eleven eyes (79%) showed improvement of vitreous hemorrhage and/or NVI. Vitreous hemorrhage improved in 7 out of 13 eyes, and NVI improved in 5 out of 5 eyes. Of the eyes with NVI, 4 out of 5 eyes showed complete resolution, the earliest occurring 3 days post injection (mean 14 days). Patients were followed for a mean of 39.8 days (range 1-95 days). No adverse events were seen.

Conclusions:: In this short follow-up period, intravitreal bevacizumab (Avastin) injection appears to be safe and well tolerated in patients with proliferative diabetic retinopathy. Rubeosis iridis responded particularly well to treatment with rapid resolution. Though vitreous hemorrhage did not fully resolve, clearance was observed in over half the patients, which subsequently permitted panretinal photocoagulation. Additional study is necessary to determine the long-term safety and efficacy of intravitreal bevacizumab in patients with proliferative diabetic retinopathy.

Keywords: diabetic retinopathy • retinal neovascularization • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×